2022 | Health Technology Assessment Division

HTAC Preliminary Recommendation on Abiraterone Acetate (250mg Tablet) and Enzalutamide (40mg Soft Gel Capsule)

Posted on October 4, 2022

Link to evidence summary Publication date: 04 October 2022 (Stakeholders may submit appeals to hta@doh.gov.ph until 18 October 2022 using the prescribe form found here: Topic Nomination ) Document Preview:

Evidence brief for 17 to 23 September 2022

Posted on September 27, 2022

For the period of 17 to 23 September 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 17– 23 September 2022 Document Preview:

[Department Circular No. 2022 – 0291] Amendment to the Department Circular 2022-0291 “Health Technology Assessment Council (HTAC) Recommendation to include Potassium Citrate 15 mEq Extended Release (ER) Tablet in the Philippine National Formulary”

Posted on September 27, 2022

Link to Department Circular No. 2022 0 0291

[Department Circular No. 2022 – 0491] Nomination to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members

Posted on September 23, 2022

[Department Circular No. 2022 – 0486] Health Technology Assessment Council (HTAC) Recommendation for the Non-inclusion of Eribulin as Second-line Treatment of Metastatic Soft Tissue sarcoma (mSTS) the Philippine National Formulary (PNF)

Posted on September 20, 2022